Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study.

BACKGROUND: Antifibrotic (AF) therapy has been shown to potentially reduce the risk of lung cancer (LC) in patients with idiopathic pulmonary fibrosis (IPF). Our study further assesses the impact of AF use and LC incidence in a real-world cohort with…

Preview only. Read the full abstract at the source